Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure

Ann Intern Med. 2000 Apr 4;132(7):525-32. doi: 10.7326/0003-4819-132-7-200004040-00003.

Abstract

Background: Liver cholestasis can be a life-threatening complication during home parenteral nutrition and may lead to combined liver-intestinal transplantation.

Objective: To assess the prevalence of home parenteral nutrition-related liver disease and its contributing factors in patients with permanent intestinal failure.

Design: Prospective cohort study.

Setting: Two approved home parenteral nutrition centers.

Patients: 90 patients with permanent intestinal failure who were receiving home parenteral nutrition were enrolled from 1985 to 1996.

Intervention: Clinical, biological, endoscopic, and ultrasonographic follow-up. Histologic examination of the liver was done in 57 patients (112 liver biopsies).

Measurements: The Kaplan-Meier method was used to determine the actuarial occurrence of chronic cholestasis and complicated home parenteral nutrition-related liver disease (bilirubin level > or =60 micromol/L [3.5 mg/dL], factor V level < or =50%, portal hypertension, encephalopathy, ascites, gastrointestinal bleeding, or histologically proven extensive fibrosis or cirrhosis). Contributing factors were assessed by using univariate and multivariate (Cox model) analysis.

Results: 58 patients (65%) developed chronic cholestasis after a median of 6 months (range, 3 to 132 months), and 37 (41.5%) developed complicated home parenteral nutrition-related liver disease after a median of 17 months (range, 2 to 155 months). Of these patients, 17 showed extensive fibrosis after 26 months (range, 2 to 148 months) and 5 had cirrhosis after 37 months (range, 26 to 77 months). The prevalence of complicated home parenteral nutrition-related liver disease was 26%+/-9% at 2 years and 50%+/-13% at 6 years. Six patients died of liver disease (22% of all deaths). In multivariate analysis, chronic cholestasis was significantly associated with a parenteral nutrition-independent risk for liver disease, a bowel remnant shorter than 50 cm in length, and a parenteral lipid intake of 1 g/kg of body weight per day or more (omega-6-rich long-chain triglycerides), whereas complicated home parenteral nutrition-related liver disease was significantly associated with chronic cholestasis and lipid parenteral intake of 1 g/kg per day or more.

Conclusion: The prevalence of complicated home parenteral nutrition-related liver disease increased with longer duration of parenteral nutrition. This condition was one of the main causes of death in patients with permanent intestinal failure. Parenteral intake of omega-6-rich long-chain triglycerides lipid emulsion consisting of less than 1 g/kg per day is recommended in these patients.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Child
  • Cholestasis, Intrahepatic / etiology
  • Cholestasis, Intrahepatic / pathology
  • Chronic Disease
  • Data Interpretation, Statistical
  • Female
  • Humans
  • Intestinal Diseases / therapy*
  • Lipids / administration & dosage
  • Liver Cirrhosis / pathology
  • Liver Diseases / etiology*
  • Liver Diseases / pathology
  • Male
  • Middle Aged
  • Parenteral Nutrition, Home / adverse effects*
  • Prospective Studies
  • Risk Factors
  • Survival Analysis
  • Time Factors

Substances

  • Lipids